Identification of decatenation G2 checkpoint impairment independently of DNA damage G2 checkpoint in human lung cancer cell lines

Cancer Research

Volumn 64, Issue 14, 2004, Pages 4826-4832

  Nakagawa, Taku ^a,b   Hayashita, Yoji ^a   Maeno, Ken ^a   Masuda, Akira ^a,c   Sugito, Nobuyoshi ^a   Osada, Hirotaka ^a   Yanagisawa, Kiyoshi ^a   Ebi, Hiromichi ^a   Shimokata, Kaoru ^b   Takahashi, Takashi ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CellSeed Inc   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; ATM PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ANTINEOPLASTIC AGENT; DNA; HELICASE; PIPERAZINE DERIVATIVE; RECQ HELICASE; WRN PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL KILLING; CHROMATID; CONTROLLED STUDY; DNA DAMAGE; GENETIC STABILITY; HUMAN; HUMAN CELL; LUNG CANCER; MITOSIS; MITOSIS INHIBITION; PRIORITY JOURNAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; RADIATION EXPOSURE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA DAMAGE; DNA HELICASES; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; G2 PHASE; HUMANS; LUNG NEOPLASMS; PIPERAZINES; RECQ HELICASES;

EID: 3142707257     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0871     Document Type: Article

References (28)

1. Minna JD. Neoplasms of the lung. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, editors. Harrison's principles of internal medicine. 15th ed. New York: McGraw-Hill; 2001. p. 562-71.
2. Statistics and Information Department, Minister's Secretariat. Vital statistics of Japan 2001, Vol. 3. Tokyo: Ministry of Health, Labour and Welfare; 2003. p. 384-411.
3. Masuda A, Takahashi T. Chromosome instability in human lung cancers: possible underlying mechanisms and potential consequences in the pathogenesis. Oncogene 2002;21:6884-97.
4. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science (Wash. DC) 1989;246:629-34.
5. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science (Wash. DC) 1996;274:1664-72.
6. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature (Lond.) 1998;396:643-9.
7. Haruki N, Harano T, Masuda A, et al. Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation. Am J Pathol 2001;159:1345-52.
8. Takahashi T, Haruki N, Nomoto S, et al. Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers. Oncogene 1999;18:4295-300.
9. Konishi H, Nakagawa T, Harano T, et al. Identification of frequent G(2) checkpoint impairment and a homozygous deletion of 14-3-3ε at 17p13.3 in small cell lung cancers. Cancer Res 2002;62:271-6.
10. 2 cycle checkpoint in mammalian cells. Nature (Lond.) 1994;372:467-70.
11. Deming PB, Cistulli CA, Zhao H, et al. The human decatenation checkpoint. Proc Natl Acad Sci USA 2001;98:12044-9.
12. Tanabe K, Ikegami Y, Ishida R, Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 1991;51:4903-8.
13. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 1994;91:1781-5.
14. Masuda A, Maeno K, Nakagawa T, Saito H, Takahashi T. Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am J Pathol 2003;163:1109-16.
15. Nishida K, Seto M, Ishida R. Different susceptibilities of postmitotic checkpoint-proficient and -deficient Balb / 3T3 cells to ICRF-193, a catalytic inhibitor of DNA topoisomerase II. Jpn J Cancer Res 2001;92:193-202.
16. 2. J Biol Chem 2000;275:19375-81.
17. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
18. Schultz LB, Chehab NH, Malikzay A, Halazonetis TD. p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J Cell Biol 2000;151:1381-90.
19. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature (Lond.) 2003;421:499-506.
20. 2-phase decatenation checkpoint is defective in Werner syndrome cells. Cancer Res 2003;63:3289-95.
21. Takahashi T, Nau MM, Chiba I, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science (Wash. DC) 1989;246:491-4.
22. 2 checkpoint through inhibition of Plk1 kinase. J Biol Chem 2002;277:36832-8.
23. Doherty SC, McKeown SR, McKelvey-Martin V, et al. Cell cycle checkpoint function in bladder cancer. J Natl Cancer Inst (Bethesda) 2003;95:1859-68.
24. Clarke DJ, Johnson RT, Downes CS. Topoisomerase II inhibition prevents anaphase chromatid segregation in mammalian cells independently of the generation of DNA strand breaks. J Cell Sci 1993;105(Pt. 2):563-9.
25. 2 and M phases of the cell cycle. Mol Cell Biol 1998;18:5797-808.
26. Hajji N, Pastor N, Mateos S, Dominguez I, Cortes F. DNA strand breaks induced by the anti-topoisomerase II bis-dioxopiperazine ICRF-193. Mutat Res 2003;530:35-46.
27. Larsen AK, Escargueil AE, Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 2003;99:167-81.
28. Andoh T, Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta 1998;1400:155-71.